Natalie Serkova
Concepts (702)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 36 | 2014 | 630 | 2.660 |
Why?
| | Cyclosporine | 20 | 2012 | 265 | 2.500 |
Why?
| | Immunosuppressive Agents | 23 | 2013 | 846 | 2.060 |
Why?
| | Sirolimus | 17 | 2013 | 281 | 1.670 |
Why?
| | Magnetic Resonance Imaging | 25 | 2024 | 3863 | 1.530 |
Why?
| | Piperazines | 6 | 2009 | 381 | 1.150 |
Why?
| | Pyrimidines | 8 | 2017 | 532 | 1.150 |
Why?
| | Metabolomics | 11 | 2021 | 727 | 1.070 |
Why?
| | Brain | 15 | 2026 | 2933 | 1.050 |
Why?
| | Energy Metabolism | 14 | 2019 | 935 | 1.050 |
Why?
| | Glucose | 14 | 2021 | 1047 | 1.040 |
Why?
| | Contrast Media | 6 | 2017 | 488 | 0.990 |
Why?
| | Antineoplastic Agents | 15 | 2022 | 2194 | 0.960 |
Why?
| | Animals | 104 | 2026 | 38058 | 0.860 |
Why?
| | Liver | 12 | 2020 | 1887 | 0.850 |
Why?
| | Biomarkers | 14 | 2019 | 4271 | 0.840 |
Why?
| | Neoplasms | 14 | 2017 | 2875 | 0.790 |
Why?
| | Neoplasms, Experimental | 3 | 2020 | 173 | 0.790 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2017 | 881 | 0.780 |
Why?
| | Cerebellar Neoplasms | 4 | 2025 | 177 | 0.710 |
Why?
| | Medulloblastoma | 4 | 2025 | 215 | 0.700 |
Why?
| | Reperfusion Injury | 11 | 2014 | 300 | 0.670 |
Why?
| | Cell Line, Tumor | 29 | 2026 | 3540 | 0.650 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2025 | 1455 | 0.650 |
Why?
| | Rats | 31 | 2015 | 5597 | 0.630 |
Why?
| | Biomarkers, Tumor | 10 | 2020 | 1313 | 0.620 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.620 |
Why?
| | Multimodal Imaging | 1 | 2020 | 124 | 0.610 |
Why?
| | Protein Kinase Inhibitors | 10 | 2018 | 969 | 0.590 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 25 | 0.580 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 127 | 0.560 |
Why?
| | Proto-Oncogene Proteins c-myc | 4 | 2025 | 167 | 0.560 |
Why?
| | Metabolome | 5 | 2019 | 384 | 0.540 |
Why?
| | Mice | 52 | 2026 | 18339 | 0.540 |
Why?
| | Ischemic Preconditioning | 2 | 2009 | 47 | 0.520 |
Why?
| | Nanoparticles | 5 | 2024 | 519 | 0.490 |
Why?
| | Brain Neoplasms | 7 | 2026 | 1318 | 0.480 |
Why?
| | Fusion Proteins, bcr-abl | 5 | 2015 | 69 | 0.480 |
Why?
| | Phospholipids | 7 | 2010 | 213 | 0.480 |
Why?
| | Everolimus | 12 | 2013 | 111 | 0.450 |
Why?
| | Rats, Wistar | 11 | 2010 | 451 | 0.450 |
Why?
| | Hypoxia | 6 | 2015 | 1199 | 0.450 |
Why?
| | Aging | 5 | 2020 | 1966 | 0.440 |
Why?
| | Body Fluids | 5 | 2019 | 70 | 0.430 |
Why?
| | Glutathione | 9 | 2023 | 375 | 0.430 |
Why?
| | Inositol | 4 | 2021 | 24 | 0.430 |
Why?
| | Glutamine | 6 | 2013 | 109 | 0.420 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2013 | 5 | 0.410 |
Why?
| | Apoptosis | 15 | 2024 | 2430 | 0.410 |
Why?
| | Organ Specificity | 4 | 2013 | 312 | 0.410 |
Why?
| | Nephritis | 1 | 2013 | 22 | 0.400 |
Why?
| | Brain Injuries | 3 | 2014 | 507 | 0.400 |
Why?
| | Positron-Emission Tomography | 10 | 2020 | 323 | 0.400 |
Why?
| | Xenograft Model Antitumor Assays | 12 | 2025 | 928 | 0.390 |
Why?
| | Lupus Nephritis | 2 | 2011 | 70 | 0.390 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 77 | 0.370 |
Why?
| | Mitochondria | 7 | 2014 | 984 | 0.370 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 103 | 0.370 |
Why?
| | Astrocytes | 5 | 2026 | 222 | 0.370 |
Why?
| | Leukemia | 2 | 2018 | 245 | 0.360 |
Why?
| | Glioma | 4 | 2024 | 425 | 0.360 |
Why?
| | Humans | 78 | 2026 | 144759 | 0.360 |
Why?
| | Blood-Brain Barrier | 3 | 2024 | 155 | 0.360 |
Why?
| | Metabolism | 3 | 2017 | 44 | 0.340 |
Why?
| | Placenta | 3 | 2009 | 780 | 0.340 |
Why?
| | Infratentorial Neoplasms | 2 | 2024 | 71 | 0.340 |
Why?
| | Disease Models, Animal | 16 | 2023 | 4557 | 0.340 |
Why?
| | Reactive Oxygen Species | 5 | 2013 | 621 | 0.330 |
Why?
| | Oxidative Stress | 5 | 2010 | 1339 | 0.330 |
Why?
| | Myocardium | 3 | 2013 | 939 | 0.330 |
Why?
| | Cell Proliferation | 14 | 2025 | 2496 | 0.330 |
Why?
| | Time Factors | 12 | 2013 | 7173 | 0.330 |
Why?
| | Benzamides | 6 | 2009 | 224 | 0.320 |
Why?
| | Kidney | 7 | 2023 | 1495 | 0.320 |
Why?
| | Kidney Diseases | 2 | 2020 | 427 | 0.310 |
Why?
| | Ependymoma | 2 | 2024 | 176 | 0.310 |
Why?
| | Seizures | 1 | 2013 | 460 | 0.310 |
Why?
| | Liver Diseases | 2 | 2010 | 304 | 0.310 |
Why?
| | Diagnostic Imaging | 2 | 2011 | 338 | 0.300 |
Why?
| | Molecular Probes | 1 | 2009 | 33 | 0.300 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 432 | 0.300 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.290 |
Why?
| | Liver Transplantation | 2 | 2007 | 823 | 0.290 |
Why?
| | Silymarin | 4 | 2016 | 147 | 0.290 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 297 | 0.290 |
Why?
| | Drug Monitoring | 3 | 2013 | 395 | 0.290 |
Why?
| | Prostatic Neoplasms | 5 | 2016 | 974 | 0.290 |
Why?
| | Lactic Acid | 7 | 2013 | 302 | 0.280 |
Why?
| | Complement C3b | 2 | 2023 | 30 | 0.280 |
Why?
| | Spermine | 1 | 2008 | 29 | 0.280 |
Why?
| | K562 Cells | 4 | 2009 | 93 | 0.270 |
Why?
| | Citric Acid | 1 | 2008 | 34 | 0.270 |
Why?
| | Graft Rejection | 5 | 2010 | 540 | 0.270 |
Why?
| | Adenosine Triphosphate | 6 | 2009 | 498 | 0.270 |
Why?
| | Hibernation | 2 | 2014 | 80 | 0.270 |
Why?
| | Adaptation, Physiological | 2 | 2009 | 570 | 0.260 |
Why?
| | Drug Design | 2 | 2007 | 173 | 0.260 |
Why?
| | Kidney Transplantation | 4 | 2010 | 704 | 0.260 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 558 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2730 | 0.250 |
Why?
| | Signal Transduction | 12 | 2026 | 5226 | 0.250 |
Why?
| | Prostate | 1 | 2008 | 158 | 0.250 |
Why?
| | Creatine | 3 | 2021 | 63 | 0.250 |
Why?
| | Altitude | 3 | 2009 | 473 | 0.250 |
Why?
| | Choline | 2 | 2009 | 136 | 0.240 |
Why?
| | Liver Failure | 1 | 2007 | 83 | 0.240 |
Why?
| | Rats, Sprague-Dawley | 11 | 2015 | 2527 | 0.240 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2026 | 38 | 0.240 |
Why?
| | Drug Therapy | 1 | 2006 | 80 | 0.240 |
Why?
| | Interleukin-1beta | 1 | 2008 | 395 | 0.240 |
Why?
| | Pneumonia | 2 | 2011 | 631 | 0.240 |
Why?
| | Dietary Supplements | 3 | 2023 | 576 | 0.230 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2026 | 93 | 0.230 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2026 | 58 | 0.230 |
Why?
| | Nanomedicine | 2 | 2024 | 46 | 0.230 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2003 | 137 | 0.230 |
Why?
| | Male | 47 | 2024 | 72315 | 0.230 |
Why?
| | Blotting, Western | 6 | 2019 | 1187 | 0.230 |
Why?
| | Transcription, Genetic | 4 | 2025 | 1496 | 0.230 |
Why?
| | Colorectal Neoplasms | 4 | 2018 | 845 | 0.230 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2016 | 49 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 50 | 0.230 |
Why?
| | Neovascularization, Pathologic | 4 | 2018 | 286 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 34 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Protein Kinases | 2 | 2004 | 315 | 0.220 |
Why?
| | Sex Characteristics | 1 | 2010 | 790 | 0.220 |
Why?
| | Macrolides | 2 | 2013 | 69 | 0.220 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 441 | 0.220 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 433 | 0.210 |
Why?
| | Drug Interactions | 6 | 2012 | 398 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 529 | 0.210 |
Why?
| | Microbubbles | 1 | 2024 | 53 | 0.210 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 458 | 0.210 |
Why?
| | Sepsis | 4 | 2013 | 640 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2012 | 2027 | 0.210 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 339 | 0.210 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 38 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2009 | 594 | 0.200 |
Why?
| | Organ Transplantation | 2 | 2004 | 247 | 0.200 |
Why?
| | Obesity | 3 | 2006 | 3077 | 0.200 |
Why?
| | TOR Serine-Threonine Kinases | 6 | 2025 | 449 | 0.200 |
Why?
| | Glycolysis | 4 | 2010 | 339 | 0.200 |
Why?
| | Autophagy | 2 | 2018 | 286 | 0.200 |
Why?
| | Autolysis | 1 | 2003 | 3 | 0.200 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1217 | 0.190 |
Why?
| | Receptors, Estrogen | 1 | 2026 | 457 | 0.190 |
Why?
| | Glomerulonephritis | 1 | 2023 | 45 | 0.190 |
Why?
| | Fatty Liver | 1 | 2005 | 251 | 0.190 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 370 | 0.190 |
Why?
| | DNA Repair | 2 | 2024 | 256 | 0.190 |
Why?
| | Lung Transplantation | 3 | 2000 | 338 | 0.180 |
Why?
| | Phosphates | 2 | 2001 | 180 | 0.180 |
Why?
| | Deoxycytidine | 2 | 2017 | 221 | 0.180 |
Why?
| | In Vitro Techniques | 5 | 2016 | 1047 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2013 | 177 | 0.180 |
Why?
| | Colonic Neoplasms | 3 | 2013 | 259 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.170 |
Why?
| | Carbon Isotopes | 3 | 2009 | 144 | 0.170 |
Why?
| | Mice, Nude | 8 | 2016 | 682 | 0.170 |
Why?
| | Radiation Tolerance | 1 | 2022 | 103 | 0.170 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 237 | 0.170 |
Why?
| | Specimen Handling | 1 | 2003 | 186 | 0.170 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 94 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 780 | 0.170 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2608 | 0.170 |
Why?
| | Tendinopathy | 1 | 2021 | 32 | 0.170 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 28 | 0.170 |
Why?
| | Lung | 8 | 2018 | 4109 | 0.160 |
Why?
| | Anticarcinogenic Agents | 2 | 2011 | 61 | 0.160 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 103 | 0.160 |
Why?
| | Heat-Shock Proteins | 3 | 2006 | 138 | 0.160 |
Why?
| | Mass Spectrometry | 4 | 2011 | 750 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2019 | 1241 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 66 | 0.160 |
Why?
| | Mammary Glands, Animal | 2 | 2014 | 128 | 0.160 |
Why?
| | Particle Accelerators | 1 | 2019 | 9 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.160 |
Why?
| | Osteoarthritis | 1 | 2022 | 196 | 0.150 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 24 | 0.150 |
Why?
| | Camptothecin | 2 | 2013 | 140 | 0.150 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 12 | 0.150 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2022 | 216 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2011 | 220 | 0.150 |
Why?
| | Heart | 1 | 2003 | 636 | 0.150 |
Why?
| | Brain Chemistry | 1 | 2000 | 116 | 0.150 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 78 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 80 | 0.150 |
Why?
| | Lactation | 2 | 2014 | 192 | 0.150 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 89 | 0.150 |
Why?
| | Perfusion | 3 | 2009 | 250 | 0.150 |
Why?
| | Fatty Acids | 2 | 2015 | 450 | 0.150 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 41 | 0.150 |
Why?
| | Endoplasmic Reticulum Stress | 3 | 2014 | 120 | 0.150 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 156 | 0.150 |
Why?
| | Inflammation | 4 | 2024 | 2878 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.140 |
Why?
| | Tumor Cells, Cultured | 4 | 2025 | 919 | 0.140 |
Why?
| | Lipogenesis | 2 | 2016 | 62 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2011 | 237 | 0.140 |
Why?
| | Whey Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Estrogens | 2 | 2026 | 380 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 442 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2018 | 34 | 0.140 |
Why?
| | Glucose Clamp Technique | 1 | 2019 | 199 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1953 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 44 | 0.140 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 39 | 0.140 |
Why?
| | Anilides | 1 | 2018 | 84 | 0.140 |
Why?
| | Polyenes | 1 | 1997 | 16 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 253 | 0.130 |
Why?
| | Histones | 2 | 2020 | 669 | 0.130 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 732 | 0.130 |
Why?
| | Rats, Zucker | 3 | 2006 | 32 | 0.130 |
Why?
| | Tracheal Stenosis | 1 | 2018 | 39 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2019 | 4154 | 0.130 |
Why?
| | Mucin-1 | 1 | 2017 | 22 | 0.130 |
Why?
| | Acute Lung Injury | 2 | 2011 | 303 | 0.130 |
Why?
| | Kinetics | 3 | 2009 | 1627 | 0.130 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.130 |
Why?
| | Phosphorylation | 4 | 2013 | 1732 | 0.130 |
Why?
| | Female | 29 | 2026 | 78271 | 0.130 |
Why?
| | Neuroprotective Agents | 1 | 2018 | 143 | 0.130 |
Why?
| | Lactates | 3 | 2006 | 83 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 164 | 0.130 |
Why?
| | Drug Synergism | 5 | 2013 | 357 | 0.130 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 84 | 0.130 |
Why?
| | Macrophages | 3 | 2019 | 1511 | 0.120 |
Why?
| | Quinazolines | 2 | 2008 | 266 | 0.120 |
Why?
| | Fibroblasts | 2 | 2016 | 1034 | 0.120 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2019 | 509 | 0.120 |
Why?
| | Tissue Extracts | 2 | 2009 | 19 | 0.120 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.120 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2013 | 21 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 85 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2017 | 194 | 0.120 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 919 | 0.120 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 62 | 0.120 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 69 | 0.120 |
Why?
| | Transcription Factors | 5 | 2014 | 1741 | 0.120 |
Why?
| | Creatinine | 4 | 2005 | 506 | 0.120 |
Why?
| | Folic Acid | 1 | 2017 | 199 | 0.120 |
Why?
| | Lipid Peroxidation | 3 | 2006 | 160 | 0.120 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2016 | 197 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2010 | 1173 | 0.120 |
Why?
| | Blood Glucose | 4 | 2019 | 2327 | 0.120 |
Why?
| | Fluorouracil | 2 | 2024 | 235 | 0.110 |
Why?
| | Liver Neoplasms | 2 | 2020 | 780 | 0.110 |
Why?
| | Neuroglia | 1 | 1996 | 172 | 0.110 |
Why?
| | Pyrazoles | 2 | 2010 | 509 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 844 | 0.110 |
Why?
| | Drug Delivery Systems | 3 | 2024 | 380 | 0.110 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 346 | 0.110 |
Why?
| | Methylamines | 2 | 2005 | 40 | 0.110 |
Why?
| | Lipid Metabolism | 4 | 2019 | 527 | 0.110 |
Why?
| | Hypothermia, Induced | 2 | 2006 | 96 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2018 | 219 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2018 | 436 | 0.110 |
Why?
| | Brain Concussion | 1 | 2023 | 640 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 12 | 0.110 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2005 | 98 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2023 | 748 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1209 | 0.110 |
Why?
| | Models, Animal | 2 | 2009 | 392 | 0.110 |
Why?
| | Homeostasis | 1 | 2018 | 640 | 0.110 |
Why?
| | Ferric Compounds | 1 | 2014 | 55 | 0.110 |
Why?
| | Rats, Inbred Lew | 4 | 2010 | 103 | 0.100 |
Why?
| | ras Proteins | 2 | 2013 | 150 | 0.100 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1980 | 0.100 |
Why?
| | Leukotrienes | 1 | 2014 | 27 | 0.100 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2014 | 34 | 0.100 |
Why?
| | Convulsants | 1 | 2013 | 8 | 0.100 |
Why?
| | CRISPR-Cas Systems | 2 | 2025 | 170 | 0.100 |
Why?
| | Dextrans | 2 | 2014 | 86 | 0.100 |
Why?
| | Kainic Acid | 1 | 2013 | 33 | 0.100 |
Why?
| | Pyridines | 1 | 2018 | 605 | 0.100 |
Why?
| | NAD | 2 | 2004 | 81 | 0.100 |
Why?
| | Treatment Outcome | 9 | 2024 | 11679 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 44 | 0.100 |
Why?
| | Urothelium | 1 | 2013 | 33 | 0.100 |
Why?
| | Brain Edema | 1 | 2013 | 62 | 0.100 |
Why?
| | Indoles | 2 | 2015 | 501 | 0.100 |
Why?
| | Azoxymethane | 1 | 2013 | 17 | 0.100 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1253 | 0.100 |
Why?
| | Cell Survival | 4 | 2016 | 1098 | 0.100 |
Why?
| | Unfolded Protein Response | 1 | 2013 | 60 | 0.100 |
Why?
| | Disease Progression | 6 | 2026 | 2847 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 29 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2452 | 0.100 |
Why?
| | Neurons | 2 | 2026 | 1640 | 0.100 |
Why?
| | Prognosis | 4 | 2017 | 4282 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 587 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 983 | 0.090 |
Why?
| | Equipment Design | 2 | 2019 | 530 | 0.090 |
Why?
| | Phytic Acid | 1 | 2012 | 35 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2015 | 215 | 0.090 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 109 | 0.090 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 154 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2925 | 0.090 |
Why?
| | Thiophenes | 1 | 2013 | 128 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Reference Values | 3 | 2019 | 797 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 250 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1499 | 0.090 |
Why?
| | Image Enhancement | 2 | 2010 | 199 | 0.090 |
Why?
| | Shock, Hemorrhagic | 1 | 2014 | 201 | 0.090 |
Why?
| | Pregnancy | 6 | 2019 | 7190 | 0.090 |
Why?
| | Insulin | 3 | 2019 | 2507 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 112 | 0.090 |
Why?
| | Mice, Transgenic | 6 | 2015 | 2182 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 623 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2010 | 76 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 193 | 0.090 |
Why?
| | RNA Polymerase II | 2 | 2025 | 351 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 82 | 0.090 |
Why?
| | Calcineurin | 1 | 2012 | 105 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2003 | 327 | 0.090 |
Why?
| | Temperature | 3 | 2014 | 679 | 0.080 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 40 | 0.080 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 610 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 194 | 0.080 |
Why?
| | Boronic Acids | 1 | 2011 | 37 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2019 | 3409 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2019 | 1095 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 205 | 0.080 |
Why?
| | Glioblastoma | 1 | 2014 | 353 | 0.080 |
Why?
| | Tacrolimus | 1 | 2012 | 196 | 0.080 |
Why?
| | Nucleotides | 2 | 2017 | 128 | 0.080 |
Why?
| | Sciuridae | 2 | 2014 | 152 | 0.080 |
Why?
| | Models, Biological | 5 | 2013 | 1821 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 2 | 2014 | 576 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
| | Electroencephalography | 1 | 2013 | 532 | 0.080 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1519 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 162 | 0.080 |
Why?
| | Benzimidazoles | 1 | 2011 | 190 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 380 | 0.080 |
Why?
| | Cell Movement | 3 | 2026 | 965 | 0.080 |
Why?
| | Complement C3-C5 Convertases | 1 | 2010 | 22 | 0.080 |
Why?
| | Hydroxybutyrates | 2 | 2010 | 15 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 92 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 760 | 0.080 |
Why?
| | Cricetulus | 1 | 2010 | 118 | 0.080 |
Why?
| | CHO Cells | 1 | 2010 | 171 | 0.080 |
Why?
| | Adult | 10 | 2013 | 40449 | 0.080 |
Why?
| | Epigenomics | 2 | 2020 | 114 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 303 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2010 | 54 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 74 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2014 | 538 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2010 | 1306 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 682 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2015 | 627 | 0.070 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 251 | 0.070 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.070 |
Why?
| | Mice, Knockout | 5 | 2020 | 3121 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 111 | 0.070 |
Why?
| | Dinoprost | 1 | 2009 | 49 | 0.070 |
Why?
| | Cell Extracts | 1 | 2009 | 21 | 0.070 |
Why?
| | Intestine, Small | 1 | 2010 | 166 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 86 | 0.070 |
Why?
| | Percussion | 1 | 2008 | 2 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 131 | 0.070 |
Why?
| | Deoxyglucose | 1 | 2009 | 51 | 0.070 |
Why?
| | Surgical Equipment | 1 | 2008 | 9 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 219 | 0.070 |
Why?
| | Mutation | 3 | 2020 | 4089 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 325 | 0.070 |
Why?
| | Sulfonamides | 2 | 2011 | 580 | 0.070 |
Why?
| | Alanine | 2 | 2013 | 171 | 0.070 |
Why?
| | Receptor, ErbB-3 | 1 | 2008 | 48 | 0.070 |
Why?
| | Macaca fascicularis | 4 | 2000 | 71 | 0.070 |
Why?
| | Complement C3d | 2 | 2023 | 67 | 0.070 |
Why?
| | Systems Biology | 1 | 2009 | 72 | 0.070 |
Why?
| | Body Weight | 4 | 2012 | 976 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 1087 | 0.070 |
Why?
| | Oxygen | 2 | 2010 | 995 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 441 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 330 | 0.060 |
Why?
| | Triglycerides | 2 | 2010 | 520 | 0.060 |
Why?
| | Lymphocytes | 1 | 2009 | 382 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1463 | 0.060 |
Why?
| | Critical Illness | 2 | 2011 | 891 | 0.060 |
Why?
| | Heart-Assist Devices | 1 | 2013 | 567 | 0.060 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.060 |
Why?
| | Tritium | 1 | 2006 | 68 | 0.060 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 107 | 0.060 |
Why?
| | Oxidative Phosphorylation | 2 | 2005 | 210 | 0.060 |
Why?
| | MicroRNAs | 1 | 2013 | 701 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 235 | 0.060 |
Why?
| | Up-Regulation | 2 | 2006 | 851 | 0.060 |
Why?
| | Age Factors | 2 | 2011 | 3333 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 573 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 229 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2013 | 212 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 614 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 561 | 0.060 |
Why?
| | Nitrogen | 1 | 2007 | 170 | 0.060 |
Why?
| | Piperidines | 1 | 2007 | 217 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 5992 | 0.060 |
Why?
| | Medical Oncology | 1 | 2009 | 332 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | Liver Failure, Acute | 1 | 2006 | 67 | 0.060 |
Why?
| | Heat-Shock Response | 1 | 2006 | 78 | 0.060 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.060 |
Why?
| | Betaine | 1 | 2005 | 65 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 100 | 0.060 |
Why?
| | Survival Rate | 3 | 2019 | 2089 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 2050 | 0.060 |
Why?
| | Lung Injury | 1 | 2008 | 237 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2012 | 826 | 0.050 |
Why?
| | Glutamic Acid | 2 | 2010 | 251 | 0.050 |
Why?
| | Methionine | 1 | 2005 | 162 | 0.050 |
Why?
| | Reference Standards | 2 | 2019 | 177 | 0.050 |
Why?
| | Glutamates | 1 | 2004 | 66 | 0.050 |
Why?
| | Seasons | 1 | 2007 | 556 | 0.050 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.050 |
Why?
| | Free Radical Scavengers | 1 | 2004 | 82 | 0.050 |
Why?
| | Heart Rate | 2 | 2009 | 855 | 0.050 |
Why?
| | Uric Acid | 1 | 2005 | 166 | 0.050 |
Why?
| | Dacarbazine | 2 | 2014 | 100 | 0.050 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 31 | 0.050 |
Why?
| | Biological Transport | 2 | 2015 | 417 | 0.050 |
Why?
| | Cholesterol | 1 | 2005 | 406 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 108 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1782 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 69 | 0.050 |
Why?
| | Proteins | 1 | 2009 | 1021 | 0.050 |
Why?
| | Hot Temperature | 1 | 2006 | 407 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2003 | 200 | 0.050 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2004 | 47 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 635 | 0.050 |
Why?
| | Drug Carriers | 1 | 2024 | 130 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 139 | 0.050 |
Why?
| | Lipids | 2 | 2021 | 710 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 29 | 0.050 |
Why?
| | Cardiac Output | 1 | 2003 | 179 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2003 | 136 | 0.050 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 70 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 222 | 0.050 |
Why?
| | Aged | 5 | 2013 | 25913 | 0.050 |
Why?
| | Necrosis | 3 | 2010 | 244 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 102 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 195 | 0.050 |
Why?
| | Rupture | 1 | 2022 | 91 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2002 | 69 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 41 | 0.050 |
Why?
| | Liposomes | 1 | 2024 | 250 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 54 | 0.040 |
Why?
| | Child | 4 | 2024 | 22633 | 0.040 |
Why?
| | Anterior Cruciate Ligament | 1 | 2022 | 101 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2009 | 928 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 2010 | 956 | 0.040 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.040 |
Why?
| | Tumor Burden | 2 | 2014 | 319 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2013 | 190 | 0.040 |
Why?
| | Succinic Acid | 2 | 2013 | 42 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 88 | 0.040 |
Why?
| | Tibia | 1 | 2022 | 176 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2001 | 85 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 120 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 459 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1047 | 0.040 |
Why?
| | Random Allocation | 3 | 2006 | 363 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 25 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 251 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 117 | 0.040 |
Why?
| | Middle Aged | 6 | 2016 | 35875 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 383 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 87 | 0.040 |
Why?
| | Ligands | 2 | 2012 | 673 | 0.040 |
Why?
| | Tunica Intima | 1 | 2000 | 79 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 129 | 0.040 |
Why?
| | Phenotype | 3 | 2016 | 3162 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2001 | 192 | 0.040 |
Why?
| | Heart Failure | 1 | 2013 | 2323 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2013 | 766 | 0.040 |
Why?
| | Sheep, Domestic | 1 | 2019 | 33 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 370 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 88 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 779 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 415 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1382 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 454 | 0.040 |
Why?
| | Knee Joint | 1 | 2022 | 426 | 0.040 |
Why?
| | Mifepristone | 1 | 2018 | 64 | 0.030 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2018 | 19 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2004 | 592 | 0.030 |
Why?
| | Salivary Glands | 1 | 2018 | 36 | 0.030 |
Why?
| | Anthropometry | 1 | 2019 | 200 | 0.030 |
Why?
| | Radiology, Interventional | 1 | 2019 | 49 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 302 | 0.030 |
Why?
| | NF-kappa B | 2 | 2013 | 661 | 0.030 |
Why?
| | Breast | 1 | 2019 | 158 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1716 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2019 | 158 | 0.030 |
Why?
| | Amino Acids | 1 | 2002 | 521 | 0.030 |
Why?
| | Citric Acid Cycle | 1 | 1997 | 59 | 0.030 |
Why?
| | Robotics | 1 | 2019 | 87 | 0.030 |
Why?
| | Cell Size | 1 | 1997 | 92 | 0.030 |
Why?
| | Digoxin | 1 | 2017 | 27 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 556 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 55 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2637 | 0.030 |
Why?
| | Cytosol | 1 | 1997 | 227 | 0.030 |
Why?
| | Cysteine | 1 | 2018 | 210 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 261 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 74 | 0.030 |
Why?
| | Rabbits | 1 | 2018 | 648 | 0.030 |
Why?
| | Aorta | 1 | 2000 | 429 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 285 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 40 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 43 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.030 |
Why?
| | Membrane Lipids | 1 | 1996 | 83 | 0.030 |
Why?
| | Heat Shock Transcription Factors | 2 | 2006 | 21 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 203 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 112 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 247 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 32 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 479 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2015 | 22 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 975 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 49 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2015 | 56 | 0.030 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 7 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 684 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 902 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 75 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 151 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 336 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10779 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 457 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 194 | 0.030 |
Why?
| | Chlorobenzenes | 1 | 2014 | 19 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 204 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 217 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 304 | 0.030 |
Why?
| | Maze Learning | 1 | 2014 | 103 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 707 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 508 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1137 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 186 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 299 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 88 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 77 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 63 | 0.020 |
Why?
| | Mice, Inbred A | 1 | 2013 | 48 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.020 |
Why?
| | Software | 1 | 2019 | 690 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 72 | 0.020 |
Why?
| | Somatomedins | 1 | 2013 | 28 | 0.020 |
Why?
| | Particle Size | 1 | 2014 | 411 | 0.020 |
Why?
| | Catalysis | 1 | 2014 | 322 | 0.020 |
Why?
| | Vacuoles | 1 | 2013 | 38 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 151 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 174 | 0.020 |
Why?
| | Mitogens | 1 | 2013 | 55 | 0.020 |
Why?
| | Cell Shape | 1 | 2013 | 57 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 172 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 476 | 0.020 |
Why?
| | Tissue Donors | 2 | 2010 | 424 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 38 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 122 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3671 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 193 | 0.020 |
Why?
| | Carcinogens | 1 | 2013 | 122 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 262 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 171 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 108 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 307 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 173 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2832 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1045 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2014 | 200 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 533 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2011 | 37 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 292 | 0.020 |
Why?
| | Self Administration | 1 | 2012 | 124 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4564 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 200 | 0.020 |
Why?
| | Sucrose | 1 | 2012 | 112 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 975 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 55 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 758 | 0.020 |
Why?
| | Nestin | 1 | 2010 | 19 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 252 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 225 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 318 | 0.020 |
Why?
| | Urethane | 1 | 2010 | 43 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2011 | 128 | 0.020 |
Why?
| | Receptors, Complement 3d | 1 | 2011 | 142 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 300 | 0.020 |
Why?
| | Neutrophils | 2 | 2006 | 1134 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 18 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 366 | 0.020 |
Why?
| | HT29 Cells | 1 | 2010 | 37 | 0.020 |
Why?
| | Adenine | 1 | 2013 | 339 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 157 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 521 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 238 | 0.020 |
Why?
| | Hydrogen | 1 | 2010 | 73 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 159 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 117 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 134 | 0.020 |
Why?
| | Limit of Detection | 1 | 2009 | 97 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 186 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2010 | 248 | 0.020 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 389 | 0.020 |
Why?
| | Portal Vein | 1 | 2010 | 114 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 207 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 41 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 57 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 423 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 110 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 227 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 596 | 0.020 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2008 | 45 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2009 | 197 | 0.020 |
Why?
| | Dura Mater | 1 | 2008 | 35 | 0.020 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 34 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1833 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 627 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 8265 | 0.020 |
Why?
| | Craniotomy | 1 | 2008 | 82 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 965 | 0.020 |
Why?
| | Pressure | 1 | 2008 | 225 | 0.020 |
Why?
| | Drug Discovery | 1 | 2009 | 155 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 627 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 557 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 592 | 0.020 |
Why?
| | Carcinoma | 1 | 2008 | 228 | 0.020 |
Why?
| | United States | 1 | 2024 | 15966 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2006 | 85 | 0.020 |
Why?
| | Peroxidase | 1 | 2006 | 168 | 0.010 |
Why?
| | Risk | 1 | 2008 | 911 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2006 | 151 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1387 | 0.010 |
Why?
| | Organ Size | 1 | 2006 | 463 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2005 | 13 | 0.010 |
Why?
| | Child, Preschool | 1 | 2020 | 11787 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3604 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2061 | 0.010 |
Why?
| | Quercetin | 1 | 2005 | 18 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2008 | 464 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1886 | 0.010 |
Why?
| | Dietary Fats | 1 | 2006 | 314 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 676 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| | Raffinose | 1 | 2003 | 29 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2010 | 916 | 0.010 |
Why?
| | Computational Biology | 1 | 2009 | 680 | 0.010 |
Why?
| | Allopurinol | 1 | 2003 | 69 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2003 | 47 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 985 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 383 | 0.010 |
Why?
| | Cell Membrane | 1 | 2006 | 706 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 32 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2273 | 0.010 |
Why?
| | Adenosine | 1 | 2003 | 255 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 179 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 405 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1490 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 863 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 379 | 0.010 |
Why?
| | Automation | 1 | 2000 | 102 | 0.010 |
Why?
| | Microchemistry | 1 | 2000 | 19 | 0.010 |
Why?
| | Calibration | 1 | 2000 | 151 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 552 | 0.010 |
Why?
| | Emulsions | 1 | 2000 | 57 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 94 | 0.010 |
Why?
| | Blood | 1 | 2000 | 109 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 354 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1813 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 7990 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2000 | 379 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 1003 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 675 | 0.010 |
Why?
| | Biopsy | 1 | 2000 | 1075 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1985 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|